Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2021-08-26 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司九届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board resolution regarding the granting of restricted shares under a stock incentive plan. It includes details about the board meeting, voting results, and the decision to grant shares to a specific executive. The document is short (949 characters) and serves as a formal announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. Therefore, it fits best under 'Board/Management Information' (MANG), which covers announcements of changes or decisions by the board or senior management.
2021-08-26 Chinese
哈药集团股份有限公司关于召开2021年上半年业绩说明会的补充公告
Investor Presentation Classification · 90% confidence The document is a short announcement regarding the scheduling and participation details of a 2021 half-year performance explanation meeting (业绩说明会). It provides logistical information for investors to join the meeting online but does not contain any financial data, analysis, or detailed report content. The document length is only 588 characters, indicating it is a brief notice rather than a full report. It is not a transcript, financial report, or regulatory filing with substantive data. Therefore, it fits best as an Investor Presentation (IP) announcement or related meeting notice. However, since it is specifically about the performance explanation meeting (业绩说明会), which is typically an investor presentation event, the classification is Investor Presentation (IP).
2021-08-20 Chinese
哈药集团股份有限公司关于召开2021年上半年业绩说明会的预告公告
Investor Presentation Classification · 90% confidence The document is a notice announcing the upcoming 2021 half-year performance explanation meeting (业绩说明会) for 哈药集团股份有限公司. It references that the 2021 half-year report has already been disclosed on August 16, 2021, and provides details about the meeting time, location, participants, and how investors can submit questions. The document itself does not contain financial statements or substantive financial data but serves as a pre-announcement for an investor call related to the half-year results. It is not the actual interim report nor a transcript but an announcement of the event where the company will discuss the interim results. Given the short length (1267 characters) and the nature of the content, this fits best as an Investor Presentation (IP) announcement or a Call Transcript (CT) precursor. However, since it is a pre-announcement of the performance explanation meeting (which is a form of investor presentation), the best classification is Investor Presentation (IP).
2021-08-15 Chinese
哈药集团股份有限公司独立董事关于公司九届十三次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding changes in accounting policies and asset impairment provisions. It references compliance with accounting standards and regulatory requirements but does not contain full financial statements or detailed financial data. The document is a formal opinion related to board matters, specifically about accounting policy changes and asset impairment, which aligns with Board/Management Information filings. It is not a full audit report or annual report, nor is it a certification or announcement of a report publication. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on board opinions, supporting this classification with high confidence.
2021-08-15 Chinese
哈药集团股份有限公司2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年半年度报告摘要' which translates to '2021 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a half-year report summary and includes substantive financial data and analysis for the period. The length is 2295 characters, which is relatively short, but the content includes actual financial figures and company performance data, not just an announcement or a link to a report. Therefore, it is a comprehensive interim/quarterly report rather than a mere announcement or certification. According to the filing definitions, this fits best under 'Interim / Quarterly Report (IR)'. H1 2021
2021-08-15 Chinese
哈药集团股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the nature of the accounting policy change, its impact on the company, and includes opinions from independent directors and the supervisory board. The document is relatively short (1751 characters) and serves as a formal announcement of the accounting policy change rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.